Sugimoto Seiichiro, Soh Junichi, Suzawa Ken, Miyoshi Kentaroh, Otani Shinji, Yamamoto Hiromasa, Okazaki Mikio, Yamane Masaomi, Oto Takahiro, Kanazawa Susumu, Kiura Katsuyuki, Toyooka Shinichi
Department of General Thoracic Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Department of Radiology, Okayama University Hospital, Okayama, Japan.
Surg Today. 2020 Aug;50(8):863-871. doi: 10.1007/s00595-020-01960-5. Epub 2020 Jan 21.
Some long-term survivors after surgery for locally advanced non-small cell lung cancer (NSCLC) treated with induction chemoradiotherapy (trimodality treatment) develop chronic pulmonary aspergillosis (CPA). The aim of our study was to assess the characteristics and outcomes of CPA that develops after trimodality treatment.
We retrospectively reviewed the data of 187 NSCLC patients who underwent trimodality treatment between 1999 and 2018.
Six male ever-smoker patients developed CPA. All 6 patients had undergone extended resection for NSCLC and had a history of either adjuvant chemotherapy (n = 3) or radiation pneumonitis (n = 4). Among the 4 patients with CPA localized in a single lung, 3 patients were treated surgically (completion pneumonectomy or cavernostomy) and 1 patient was treated with antifungal therapy alone. Both treatments led to the improved control of CPA. In contrast, patients with CPA in both lungs were not candidates for surgery, and died of CPA. The survival rates after trimodality treatment in the CPA group and the group without CPA were comparable (10-year survival rate, 50.0% vs. 57.6%, P = 0.59).
The early diagnosis of CPA localized in a single lung after NSCLC surgery is critical to improving control and survival in patients with CPA.
一些接受诱导放化疗(三联疗法)治疗的局部晚期非小细胞肺癌(NSCLC)患者术后长期存活者会发生慢性肺曲霉病(CPA)。我们研究的目的是评估三联疗法后发生的CPA的特征和结局。
我们回顾性分析了1999年至2018年间接受三联疗法的187例NSCLC患者的数据。
6例男性曾经吸烟者发生了CPA。所有6例患者均接受了NSCLC扩大切除术,并有辅助化疗史(n = 3)或放射性肺炎史(n = 4)。在4例单肺局限性CPA患者中,3例接受了手术治疗(全肺切除术或空洞造口术),1例仅接受抗真菌治疗。两种治疗均使CPA得到更好的控制。相比之下,双肺CPA患者不适合手术,死于CPA。CPA组和无CPA组三联疗法后的生存率相当(10年生存率,50.0%对57.6%,P = 0.59)。
NSCLC手术后单肺局限性CPA的早期诊断对于改善CPA患者的控制和生存至关重要。